Mar 12, 2012Galmed Phase II Aramchol Clinical Trial Successfully Demonstrates Safety and Positive Short-Term Effects for Treating Fatty Liver Disease
Galmed Medical Research Ltd. announced today that Phase-II randomized, double blind trial results of its novel drug Aramchol for treating Fatty Liver Disease (NAFLD) has successfully confirmed the...
Dec 21, 2011
Galmed Pharmaceuticals today announced the completion of a $5.5M financing round in the company. The round was led by private Venture Capital firm CH-Health, headed by Mr. Haim Hurvitz, a board...